Lymphoma, T-Cell, Peripheral: all 607 studies
Page 4 of 7. Open to participants first (133), then studies with results posted, then the rest; newest registration first within each.
- Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell MalignanciesCompletedNCT05290155Phase 1
- A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological MalignanciesCompletedNCT05269940Phase 1/2
- Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCLWithdrawnNCT05239910Phase 2
- Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid TumorsCompletedNCT05225584Phase 1
- An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory LymphomaStatus unknownNCT05208853Early Phase 1
- Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell LymphomaStatus unknownNCT05179213Phase 2
- A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).TerminatedNCT05156229Phase 1
- Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCLStatus unknownNCT05149170Phase 2
- A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCLSuspendedNCT05138458Phase 1/2
- A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)CompletedNCT05137847
- An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)No longer availableNCT05131438
- Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell LymphomasTerminatedNCT05105412Phase 1/2
- PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell LymphomaTerminatedNCT05083208Phase 1
- CD7 CAR T-cell for R/R CD7+ T Cell LymphomaStatus unknownNCT05059912Phase 2
- Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell LymphomaCompletedNCT05058755Not applicable
- Brentuximab Vedotin in Combination With CHEP in Patient With PTCLStatus unknownNCT05006664Phase 2
- Study of Lacutamab in Peripheral T-cell LymphomaActive, not recruitingNCT04984837Phase 2
- GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell LymphomaStatus unknownNCT04917250Phase 2
- Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell LymphomaStatus unknownNCT04899414Phase 2
- Immune Responses to COVID-19 Vaccination in Lymphoma PatientsCompletedNCT04858568
- Sintilimab in Combination With Chidamide in Refractory and Relapsed AITLStatus unknownNCT04831710Phase 2
- Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell MalignanciesSuspendedNCT04828174Phase 1
- Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaWithdrawnNCT04795869Phase 2
- Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic MalignanciesStatus unknownNCT04767308Early Phase 1
- Mogamulizumab Q4week Dosing in Participants With R/R CTCLActive, not recruitingNCT04745234Phase 2
- Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell LymphomaActive, not recruitingNCT04712864Phase 1
- Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)CompletedNCT04702503Phase 1
- Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) PatientsStatus unknownNCT04696705Early Phase 1
- Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTLStatus unknownNCT04676789Phase 2
- Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCLActive, not recruitingNCT04668690Phase 3
- CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.Status unknownNCT04653649Phase 1/2
- A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）Status unknownNCT04615468Phase 2
- Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) TrialTerminatedNCT04602065Phase 1/2
- Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCLTerminatedNCT04548700Phase 1
- Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaActive, not recruitingNCT04526834Phase 1
- A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell LymphomaStatus unknownNCT04490590Phase 4
- CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label StudyStatus unknownNCT04480788Phase 1
- Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional ChemotherapyStatus unknownNCT04480125Phase 2
- Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell LymphomaActive, not recruitingNCT04480099Phase 2
- A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell LymphomaStatus unknownNCT04470141Phase 2
- The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).Status unknownNCT04457830Phase 2
- A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT04444141Phase 1/2
- A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell LymphomaTerminatedNCT04425070Phase 1/2
- Predictive Value of a SNP Signature and Liquid Biopsy in Natural Killer T-cell LymphomaStatus unknownNCT04423536
- GPED Regimen for Relapsed/Refractory or Advanced ENKTCLStatus unknownNCT04405375Phase 2
- Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell LymphomaStatus unknownNCT04338282Phase 2
- Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCLStatus unknownNCT04337593Phase 2
- Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell LymphomasWithdrawnNCT04334174Phase 2
- Rituximab Combined With Chidamide and Lenalidomide for r/r AITLStatus unknownNCT04319601Not applicable
- Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II StudyStatus unknownNCT04296786Phase 2
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
- Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell LymphomaWithdrawnNCT04233697Phase 1
- Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell LymphomaWithdrawnNCT04230330Phase 1
- LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell LymphomaTerminatedNCT04219319Phase 1
- REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)TerminatedNCT04218825Phase 2
- CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell MalignanciesStatus unknownNCT04162340Phase 1
- Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.Status unknownNCT04118868Phase 1
- A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaStatus unknownNCT04108325Phase 1
- Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell LymphomaStatus unknownNCT04096690Phase 2
- A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesActive, not recruitingNCT04072458Phase 1
- A Study of Bortezomib Combined With CHEP in Peripheral T Cell LymphomaStatus unknownNCT04061772Phase 2
- PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell LymphomaStatus unknownNCT04040491Phase 4
- PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell LymphomaStatus unknownNCT04038411Phase 4
- γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)Status unknownNCT04028440Early Phase 1
- CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)WithdrawnNCT04021082Phase 2/3
- BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)CompletedNCT04018248Phase 1
- Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte MalignanciesStatus unknownNCT04008394Phase 1
- CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic LeukemiaStatus unknownNCT04004637Phase 1
- A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory MalignanciesWithdrawnNCT03999658Phase 2
- Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell LymphomaStatus unknownNCT03952572Phase 3
- Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell LymphomaCompletedNCT03936452Phase 2
- Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell LymphomaActive, not recruitingNCT03922724Phase 2
- Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory LymphomaStatus unknownNCT03921879Phase 1
- Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell LymphomaStatus unknownNCT03853044Phase 2
- PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR StudyTerminatedNCT03837457Phase 2
- A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell LymphomaStatus unknownNCT03776279Phase 2
- Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast CancerStatus unknownNCT03775525Phase 1
- ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell LymphomaCompletedNCT03742921
- Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell LymphomaStatus unknownNCT03730740Phase 2
- PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell LymphomaStatus unknownNCT03701022Phase 2
- Allo-HSCT as First-line Consolidation in High-risk PTCLStatus unknownNCT03672084
- VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma PatientsStatus unknownNCT03671850Phase 2
- Treatment of Newly Diagnosed Peripheral T-cell LymphomaStatus unknownNCT03631862Phase 4
- Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell LymphomaStatus unknownNCT03630731Phase 2
- Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma SubjectsStatus unknownNCT03629873Phase 2
- SIMPLE Chemotherapy for NK Lymphoma/LeukaemiaStatus unknownNCT03623087Phase 3
- Anlotinib for Advanced and Refractory Natural Killer /T-cell LymphomaCompletedNCT03618238Phase 2
- Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma PatientsStatus unknownNCT03617432Phase 2
- Pacritinib in Relapsed/Refractory Lymphoproliferative DisordersTerminatedNCT03601819Phase 1
- Tofacitinib Combined With Chidamide in R/R ENKTCLStatus unknownNCT03598959Phase 2
- PLM60 for Peripheral T Cell Lymphoma (PTCL)WithdrawnNCT03553914Phase 1/2
- Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell LymphomaStatus unknownNCT03553537Phase 3
- Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell LymphomaTerminatedNCT03552692Phase 2
- Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)Status unknownNCT03502629Phase 2
- Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With GemcitabineCompletedNCT03496779Phase 2
- Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell LymphomaCompletedNCT03487133Phase 2
- A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)Active, not recruitingNCT03385226Phase 2
- SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell LymphomaStatus unknownNCT03363555Phase 2
- Pralatrexate for Relapsed or Refractory Peripheral T-cell LymphomaCompletedNCT03356678
- Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCLWithdrawnNCT03355768Phase 3